Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 500 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 500 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $30.00, for a total transaction of $15,000.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $336,690. This represents a 4.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Anthony Bergmann also recently made the following trade(s):

• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Stock Down 0.3%

Shares of CAPR stock traded down $0.09 on Wednesday, reaching $29.51. 803,008 shares of the stock were exchanged, compared to its average volume of 955,468. The stock has a market cap of $1.71 billion, a P/E ratio of -12.72 and a beta of 0.39. The firm has a 50 day moving average of $30.26 and a two-hundred day moving average of $28.40. Capricor Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, equities research analysts predict that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CAPR has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. B. Riley Financial raised their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Finally, Piper Sandler reiterated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $48.36.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its stake in shares of Capricor Therapeutics by 12.4% during the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares in the last quarter. KBC Group NV acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at about $44,000. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $43,000. Nuveen LLC raised its holdings in shares of Capricor Therapeutics by 2.1% during the 4th quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock valued at $2,625,000 after buying an additional 1,878 shares during the period. Finally, State of Wyoming lifted its position in Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 1,913 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.